By Britain Eakin ( February 11, 2021, 7:52 PM EST) -- Attorneys for Mylan and Merck & Co. Inc. faced tough questions from a Patent Trial and Appeal Board judge Thursday in Mylan's bid to knock out a patent on Merck's blockbuster diabetes drugs Januvia and Janumet, a case that could have implications for an ongoing multidistrict litigation fight....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.